![1]()
News
HM20 Virtual: Improved supervision of residents
September 9, 2020
Resident supervision is driven by three factors: what residents need, what residents want, and what the supervisor can provide.
![1]()
News
Minidose edoxaban may safely cut AFib stroke risk in the frail, very elderly
September 3, 2020
Those who took the factor Xa inhibitor edoxaban (Savaysa) at the off-label dosage of 15 mg once daily showed a two-thirds drop in risk for stroke or systemic embolism, compared with patients who received placebo.
![1]()
News
REALITY trial supports restrictive transfusion in anemic MI
September 2, 2020
Restrictive transfusion proves more effective and less costly than liberal transfusion.
![1]()
News
First randomized trial reassures on ACEIs, ARBs in COVID-19
September 2, 2020
The BRACE CORONA study found no difference in key outcomes between patients continuing versus stopping their medication.
News
Pandemic worsens disparities in GI and liver disease
September 1, 2020
Creative local solutions are needed to address screening and health care problems.
![1]()
News
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
September 1, 2020
“Who’s happy with the HOME-PE trial? I think everybody.” – Dr. Stavros V. Konstantinides
![1]()
News
ESC’s revised NSTE-ACS guidelines embrace hsT, personalized anti-ischemia treatments
August 31, 2020
The first guideline update in 5 years for non ST-elevation ACS stresses high sensitivity troponin for diagnosis and tailored antiplatelet treatments.
![1]()
News
Gut bacteria linked to cardiovascular, other health conditions
August 31, 2020
“Microbiota and their metabolites ... could serve as potential therapeutic targets for the maintenance of health and prevention and treatment of cardiovascular diseases.”
![1]()
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
August 31, 2020
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
August 30, 2020
The 25% cut in primary endpoints among HFrEF patients on empagliflozin matched the benefit seen before from dapagliflozin in DAPA-HF.
